What question did this study set out to answer?

To evaluate real-world clinical characteristics, prescribing patterns, effectiveness, persistence, patient-reported outcomes, and safety associated with baricitinib in patients with rheumatoid arthritis.

September 16, 2023Rheumatology and TherapyOpen Access

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

View Full Paper

Ask AI

Bookmark

Authors

BHBlanca Hernández‐CruzAndalusian Health Service UKUta KiltzRheumazentrum Ruhrgebiet JAJérôme AvouacInserm

Discussion

Member takes

Implication

Systematic review reveals clinical effectiveness and sustained drug persistence with baricitinib in rheumatoid arthritis, indicating consistent real-world benefits across treatment lines.

Key Points

To evaluate real-world clinical characteristics, prescribing patterns, effectiveness, persistence, patient-reported outcomes, and safety associated with baricitinib in patients with rheumatoid arthritis.
Conducted a PRISMA systematic literature review searching MEDLINE, EMBASE, and evidence-based medicine databases from January 2016 through September 2022.
Manually searched ACR and EULAR conference repositories through November 2022 to retrieve relevant real-world abstracts.
Identified 11,472 initial records and included 70 observational studies (30 full-text manuscripts and 40 conference abstracts).
Patients were predominantly older females (aged 51–71 years) with established disease duration (mean 4–19 years), with the 4 mg dose most frequently prescribed (range 22–100%) following biologic DMARD failure.
Clinical Disease Activity Index (CDAI) remission occurred in 8.7–60% of patients at week 12 and low disease activity in 20.2–81.6% at week 24, while Simple Disease Activity Index (SDAI) remission was 12% at week 4 and reached 45.4% at week 24.
Drug persistence equaled or exceeded rates seen with anti-tumor necrosis factor therapies, accompanied by improvements in physical function and pain without new safety signals.

Cite This Study

Hernández‐Cruz et al. (2023) studied this question.

synapsesocial.com/papers/6a7037d2e5469ee92be0f7e2 https://doi.org/10.1007/s40744-023-00591-9

View Full Paper

Ask AI

Bookmark

Implication

Systematic review reveals clinical effectiveness and sustained drug persistence with baricitinib in rheumatoid arthritis, indicating consistent real-world benefits across treatment lines.

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

Discussion

Member takes

Implication

Key Points

Cite This Study

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider